Poster Abstracts - C717

Dendritic Cell-based Vaccine for Complementary Therapy of High Grade Glioma Patients using the CliniMACS Platform for Large-scale Clinical Production

Identification: 1001

Modeling Tumor Immuno-Dynamics to Predict Patient Survival & Immunotherapy Efficacy

Identification: 1002

Targeting myeloid derived suppressor cells to attenuate glioblastoma growth

Identification: 1003

An analysis of expression of Immune checkpoint biomarkers in 15,454 patients with adverse pathology after radical prostatectomy: initial results from the Decipher GRID

Identification: 1004

Class II-restricted tumor antigens can function to either promote or inhibit vaccine induced protective anti-tumor responses

Identification: 1005

Engineering adoptive T cell therapy for efficacy in ovarian cancer

Identification: 1007

Myeloid Derived Suppressor Cells Arising from Tumor Resections Severely Suppresses Natural Killer Cells ex vivo

Identification: 1008

Depletion of tumor-infiltrating regulatory T cells with anti-CD25 requires Fc-optimization and synergizes with PD-1 blockade to eradicate established tumors

Identification: 1010

Humanized mouse; A model for understanding tumor-immune system interactions

Identification: 1012

HIFU improves the therapeutic efficacy of dendritic cell vaccine in mouse melanoma model

Identification: 1014